Pioglitazone (pioglitazone)

Pioglitazone is approved for: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; As monotherapy in patients not adequately controlled by diet and exercise; In combination with a sulfonylurea, metformin, or insulin when diet, exercise and a single agent do not achieve adequate control; Not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis; Not recommended in patients with NYHA Class III or IV heart failure (not studied pre-approval at these stages). It is a pioglitazone (Thiazolidinedione), originally marketed as Actos; Actoplus Met and Actoplus Met XR (with metformin) and Duetact (with glimepiride) are the originator combinations by Takeda Pharmaceutical Company (first US approval 1999).

Pioglitazone (Thiazolidinedione (TZD), insulin sensitiser, PPAR-gamma agonist, originally Actos; Actoplus Met and Actoplus Met XR (with metformin) and Duetact (with glimepiride) are the originator combinations by Takeda Pharmaceutical Company (first US approval 1999)) Pioglitazone makes the body more sensitive to its own insulin. It activates a receptor in fat and muscle cells that turns on genes involved in handling glucose, so the liver releases less sugar and muscle takes more of it up. Because it needs some insulin to work, it is used in type 2 diabetes rather than type 1. Start 15 mg or 30 mg orally once daily as monotherapy in patients not adequately controlled by diet and exercise, or when adding to an existing regimen where the patient is not controlled on a single agent. The dose may be increased in increments of 15 mg up to a maximum of 45 mg once daily. In patients with congestive heart failure (NYHA Class I or II), start at 15 mg once daily and titrate in in

Standard dosing for pioglitazone: Start 15 mg or 30 mg orally once daily as monotherapy in patients not adequately controlled by diet and exercise, or when adding to an existing regimen where the patient is not controlled on a single agent. The dose may be increased in increments of 15 mg up to a maximum of 45 mg once daily. In patients with congestive heart failure (NYHA Class I or II), start at 15 mg once daily and titrate in increments of 15 mg with careful monitoring for weight gain, oedema or signs of cardiac failure. Dose adjustments: Renal impairment: no dose adjustment recommended - the serum elimination half-life of pioglitazone and its active metabolites M-III and M-IV is unchanged in moderate (CrCl 30-60 mL/min) to severe (CrCl less than 30 mL/min) renal impairment. Hepatic impairment: use with caution and monitor liver tests; avoid in active liver disease. Heart failure: only for NYHA Class I-II, starting at 15 mg with close monitoring; contraindicated in NYHA Class III-IV. Allow three months of therapy before judging HbA1c response unless glycaemic control deteriorates.

Pioglitazone (Thiazolidinedione (TZD), insulin sensitiser, PPAR-gamma agonist, originally Actos; Actoplus Met and Actoplus Met XR (with metformin) and Duetact (with glimepiride) are the originator combinations by Takeda Pharmaceutical Company (first US approval 1999)) Pioglitazone makes the body more sensitive to its own insulin. It activates a receptor in fat and muscle cells that turns on genes involved in handling glucose, so the liver releases less sugar and muscle takes more of it up. Because it needs some insulin to work, it is used in type 2 diabetes rather than type 1. Start 15 mg or 30 mg orally once daily as monotherapy in patients not adequately controlled by diet and exercise, or when adding to an existing regimen where the patient is not controlled on a single agent. The dose may be increased in increments of 15 mg up to a maximum of 45 mg once daily. In patients with congestive heart failure (NYHA Class I or II), start at 15 mg once daily and titrate in in

Pioglitazone (Thiazolidinedione (TZD), insulin sensitiser, PPAR-gamma agonist, originally Actos; Actoplus Met and Actoplus Met XR (with metformin) and Duetact (with glimepiride) are the originator combinations by Takeda Pharmaceutical Company (first US approval 1999)) Pioglitazone makes the body more sensitive to its own insulin. It activates a receptor in fat and muscle cells that turns on genes involved in handling glucose, so the liver releases less sugar and muscle takes more of it up. Because it needs some insulin to work, it is used in type 2 diabetes rather than type 1. Start 15 mg or 30 mg orally once daily as monotherapy in patients not adequately controlled by diet and exercise, or when adding to an existing regimen where the patient is not controlled on a single agent. The dose may be increased in increments of 15 mg up to a maximum of 45 mg once daily. In patients with congestive heart failure (NYHA Class I or II), start at 15 mg once daily and titrate in in

Pioglitazone (Thiazolidinedione (TZD), insulin sensitiser, PPAR-gamma agonist, originally Actos; Actoplus Met and Actoplus Met XR (with metformin) and Duetact (with glimepiride) are the originator combinations by Takeda Pharmaceutical Company (first US approval 1999)) Pioglitazone makes the body more sensitive to its own insulin. It activates a receptor in fat and muscle cells that turns on genes involved in handling glucose, so the liver releases less sugar and muscle takes more of it up. Because it needs some insulin to work, it is used in type 2 diabetes rather than type 1. Start 15 mg or 30 mg orally once daily as monotherapy in patients not adequately controlled by diet and exercise, or when adding to an existing regimen where the patient is not controlled on a single agent. The dose may be increased in increments of 15 mg up to a maximum of 45 mg once daily. In patients with congestive heart failure (NYHA Class I or II), start at 15 mg once daily and titrate in in

Pioglitazone makes the body more sensitive to its own insulin. It activates a receptor in fat and muscle cells that turns on genes involved in handling glucose, so the liver releases less sugar and muscle takes more of it up. Because it needs some insulin to work, it is used in type 2 diabetes rather than type 1. Technically: Thiazolidinedione that acts as an agonist at the peroxisome proliferator-activated receptor gamma (PPAR-gamma, predominantly the PPAR-gamma1 isoform). Activation increases transcription of insulin-responsive genes involved in glucose uptake and lipid metabolism, increases peripheral insulin sensitivity, and reduces hepatic gluconeogenesis, lowering fasting and postprandial glucose and HbA1c. It also shifts fluid balance, which produces dose-related plasma volume expansion and peripheral oedema, and is the reason for the heart failure warning.

Pioglitazone (Thiazolidinedione (TZD), insulin sensitiser, PPAR-gamma agonist, originally Actos; Actoplus Met and Actoplus Met XR (with metformin) and Duetact (with glimepiride) are the originator combinations by Takeda Pharmaceutical Company (first US approval 1999)) Pioglitazone makes the body more sensitive to its own insulin. It activates a receptor in fat and muscle cells that turns on genes involved in handling glucose, so the liver releases less sugar and muscle takes more of it up. Because it needs some insulin to work, it is used in type 2 diabetes rather than type 1. Start 15 mg or 30 mg orally once daily as monotherapy in patients not adequately controlled by diet and exercise, or when adding to an existing regimen where the patient is not controlled on a single agent. The dose may be increased in increments of 15 mg up to a maximum of 45 mg once daily. In patients with congestive heart failure (NYHA Class I or II), start at 15 mg once daily and titrate in in

Actos (Takeda) is the innovator reference product in 15 mg, 30 mg and 45 mg tablets; pioglitazone is off patent and generics are approved in the US, India and Bangladesh. Because TZDs are highly bioequivalent-sensitive with a narrow tolerability profile (fluid retention), generics should be substituted only where the local regulator has approved them as bioequivalent to the reference product. Bangladeshi and Indian products are locally registered (DGDA / CDSCO) rather than FDA or EMA approved; compare the strength, since the local market has far more 15 mg and 30 mg products than 45 mg. Manufacturers supplying pioglitazone generic versions include ACME Laboratories Ltd., Drug International Ltd., Eris Lifesciences Ltd., Incepta Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Ltd., Mankind Pharma Ltd., Medimet Pharmaceuticals Ltd.. Brands registered in Bangladesh include Actose, Diapiotab, Diatus, Glitazon, Lit, Ogli.

Pioglitazone (Thiazolidinedione (TZD), insulin sensitiser, PPAR-gamma agonist, originally Actos; Actoplus Met and Actoplus Met XR (with metformin) and Duetact (with glimepiride) are the originator combinations by Takeda Pharmaceutical Company (first US approval 1999)) Pioglitazone makes the body more sensitive to its own insulin. It activates a receptor in fat and muscle cells that turns on genes involved in handling glucose, so the liver releases less sugar and muscle takes more of it up. Because it needs some insulin to work, it is used in type 2 diabetes rather than type 1. Start 15 mg or 30 mg orally once daily as monotherapy in patients not adequately controlled by diet and exercise, or when adding to an existing regimen where the patient is not controlled on a single agent. The dose may be increased in increments of 15 mg up to a maximum of 45 mg once daily. In patients with congestive heart failure (NYHA Class I or II), start at 15 mg once daily and titrate in in